Norepinephrine increases NADPH oxidase-derived superoxide in human peripheral blood mononuclear cells via α-adrenergic receptors.
Many diseases associated with sympathoexcitation also exhibit elevated reactive oxygen species (ROS). A recent animal study indicated that exogenous administration of the sympathetic neurotransmitter norepinephrine (NE) increased systemic ROS via circulating leukocytes. The mechanisms contributing to this effect of NE and whether these findings can be translated to humans is unknown. Thus we tested the hypothesis that NE increases superoxide production in human peripheral blood mononuclear cells (PBMCs) via NADPH oxidase. Primary human PBMCs were freshly isolated from healthy young men and placed in culture. After NE (50 pg/ml, 50 ng/ml, and 50 μg/ml concentrations) or control treatments, NADPH oxidase mRNA expression (gp91(phox), p22(phox), and p67(phox)) was assessed using real-time RT-PCR, and intracellular superoxide production was measured using dihydroethidium fluorescence. PBMCs were also treated with selective adrenergic agonists-antagonists to determine the receptor population involved. In addition, CD14(+) monocyte-endothelial cell adhesion was determined using a fluorescent-based assay. NE significantly increased NADPH oxidase gene expression and intracellular superoxide production in a time-dependent manner (superoxide: 0.9 ± 0.2 fold, 6 h vs. 3.0 ± 0.3 fold, 36 h; NE, 50 μg/ml; P < 0.05). The sustained increase in NE-induced superoxide production was primarily mediated via α-adrenergic receptors, preferentially α2-receptors. The NADPH oxidase blocker diphenylene iodonium and protein kinase C inhibitor Staurosporine significantly attenuated NE-induced increases in superoxide production. Importantly, NE treatment increased CD14(+) monocyte-endothelial cell adhesion. These findings indicate for the first time that NE increases superoxide production in freshly isolated primary human PBMCs via NADPH oxidase through α-adrenergic receptors, an effect facilitating monocyte adhesion to the endothelium.
Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri;
Shekhar H
SH
Deo
Nathan T
NT
Jenkins
Jaume
J
Padilla
Alan R
AR
Parrish
Paul J
PJ
Fadel
D000328:Adult; D002448:Cell Adhesion; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000201:enzymology*; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D009000:Monocytes / Q000502:physiology; D019255:NADPH Oxidases / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology*; D011493:Protein Kinase C; D021122:Protein Subunits; D060888:Real-Time Polymerase Chain Reaction; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013481:Superoxides / Q000378:metabolism*
D018950:Lipopolysaccharide Receptors; D021122:Protein Subunits; D011942:Receptors, Adrenergic, alpha; D013481:Superoxides; D019255:NADPH Oxidases; D011493:Protein Kinase C; D009638:Norepinephrine
oxidative stress; reactive oxygen species; sympathetic nerve activity